

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

Joshua Sanchez Felix¹, Donaldo Emiliano Silva López², Sandra Valeria Zúñiga Torres³, Angel Augusto Ornelas Guzmán⁴, Luis Enrique Pacheco Moncada⁵, Walter Ivan Abitia Amarillas¹

¹Universidad Autonoma de Sinaloa. Sinaloa, México.

²Tecnológico de Monterrey Campus Monterrey. Monterrey, Nuevo Leon, Mexico.

³Benemérita Universidad Autónoma de Aguascalientes. Aguascalientes, Mexico.

⁴Universidad de Guanajuato. Guanajuato, Mexico.

⁵Universidad Autonoma de Queretaro. Queretaro, Mexico.

ABSTRACT

Autoimmune diseases (AIDs) are characterized by chronic inflammation and immune dysregulation, significantly increasing the risk of cardiovascular events (CVE). The identification and utilization of reliable biomarkers to predict CVE in patients with AIDs hold promise for improving early detection, risk stratification, and targeted intervention strategies. This article explores the current evidence supporting the role of biomarkers, including inflammatory mediators, endothelial dysfunction markers, autoantibodies, and novel genomic and proteomic signatures. Additionally, we discuss their clinical applicability, limitations, and integration into routine practice. Understanding the interplay between biomarkers and the pathophysiological mechanisms underlying cardiovascular complications in AIDs may pave the way for precision medicine approaches, optimizing outcomes in this vulnerable population.

KEYWORDS: Autoimmune diseases, cardiovascular events, biomarkers, inflammation, risk stratification, endothelial dysfunction, precision medicine.

ARTICLE DETAILS

Published On:
22 May 2025

Available on:
<https://ijmscrs.com/>

INTRODUCTION

Cardiovascular diseases (CVDs) represent a leading cause of morbidity and mortality worldwide. In individuals with autoimmune diseases (AIDs), such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis (SSc), the risk of cardiovascular events (CVE) is disproportionately higher compared to the general population. This increased risk is driven by a complex interplay of systemic inflammation, immune dysregulation, and traditional cardiovascular risk factors. While advances in the management of AIDs have improved survival, these patients remain at elevated risk for adverse cardiovascular outcomes, necessitating novel strategies for early detection and prevention.^{1,2}

Biomarkers have emerged as pivotal tools in identifying at-risk individuals, elucidating disease mechanisms, and guiding therapeutic interventions. In the context of AIDs, biomarkers serve to bridge the gap between traditional clinical evaluation

and the molecular and immunological pathways contributing to cardiovascular pathology. Inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), markers of endothelial dysfunction like asymmetric dimethylarginine (ADMA), and autoantibodies, including anti-phospholipid antibodies, have been linked to heightened cardiovascular risk in AID populations.²

Recent advances in omics technologies have further expanded the biomarker landscape, uncovering novel genomic, transcriptomic, and proteomic signatures associated with CVE in AIDs. These biomarkers offer the potential to enhance risk stratification, allowing for the identification of high-risk patients who may benefit from early and aggressive cardiovascular prevention strategies. However, challenges remain in translating these findings into routine clinical practice, including issues of specificity, reproducibility, and accessibility.^{2,3}

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

This article provides a comprehensive review of the current evidence regarding biomarkers implicated in the prediction of CVD in AIDs. We discuss their pathophysiological relevance, clinical utility, and potential role in guiding therapeutic interventions. By integrating insights from basic science, translational research, and clinical studies, this work aims to highlight the transformative potential of biomarkers in addressing the unmet cardiovascular needs of patients with AIDs.⁴

Medical Indications for the Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases

The incorporation of biomarkers into clinical practice has revolutionized the ability to predict cardiovascular (CV) events in patients with autoimmune diseases. These conditions, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis, are frequently associated with heightened systemic inflammation and immune dysregulation, both of which contribute to accelerated atherosclerosis and increased cardiovascular morbidity and mortality. The identification and utilization of specific biomarkers in this population can facilitate early risk stratification, therapeutic decision-making, and disease monitoring.⁴

Key Biomarkers and Their Clinical Relevance

1. Inflammatory Biomarkers

- **C-reactive protein (CRP):** High-sensitivity CRP (hs-CRP) is a well-established marker of systemic inflammation. Elevated hs-CRP levels are predictive of adverse CV outcomes and are often disproportionately higher in patients with autoimmune conditions due to persistent inflammation.⁵
- **Erythrocyte sedimentation rate (ESR):** Although nonspecific, ESR correlates with inflammatory activity in autoimmune diseases and may indirectly reflect vascular inflammation and atherosclerotic risk.⁶
- **Interleukin-6 (IL-6):** IL-6 plays a pivotal role in autoimmune pathogenesis and promotes endothelial dysfunction and prothrombotic states. Elevated IL-6 levels have been associated with increased CV events in patients with RA and other autoimmune disorders.⁶

2. Markers of Endothelial Dysfunction

- **Asymmetric dimethylarginine (ADMA):** ADMA is an endogenous inhibitor of nitric oxide synthase, contributing to endothelial dysfunction. Elevated ADMA levels are correlated with increased arterial stiffness and CV risk in autoimmune populations.⁶
- **Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1):** These markers indicate endothelial activation and are often elevated in autoimmune diseases, serving as potential predictors of CV events.⁶

3. Lipid Biomarkers and Lipoprotein Dysfunction

- **Oxidized low-density lipoprotein (oxLDL):** Autoimmune diseases are frequently associated with the generation of oxLDL, which exacerbates atherogenesis and correlates with plaque instability.⁶
- **Apolipoprotein B (ApoB):** ApoB-containing lipoproteins are more accurate predictors of atherosclerotic CV risk compared to traditional lipid profiles.
- **Lipoprotein(a) [Lp(a)]:** Elevated Lp(a) levels are common in autoimmune diseases and contribute to atherothrombotic events.⁶

4. Autoantibodies as CV Biomarkers

- **Anti-phospholipid antibodies (aPL):** Frequently present in systemic autoimmune diseases, aPLs are strongly associated with thrombotic events and accelerated atherosclerosis. Their detection is critical in stratifying CV risk in conditions such as antiphospholipid syndrome (APS) and SLE.⁷
- **Anti-oxidized LDL antibodies:** These antibodies signify heightened oxidative stress and may predict CV events in autoimmune patients.⁷

5. Cardiac-Specific Biomarkers

- **Troponins:** Cardiac troponins, even at subclinical elevations, are indicative of myocardial injury and have been increasingly recognized as predictors of CV events in autoimmune populations, particularly in RA and SLE.⁸
- **N-terminal pro-brain natriuretic peptide (NT-proBNP):** Elevated levels of NT-proBNP reflect cardiac stress and dysfunction, often occurring in patients with systemic inflammation and associated myocardial involvement.⁸

Clinical Utility of Biomarkers in Risk Stratification

- **Early Detection of Subclinical Cardiovascular Disease:** Biomarkers such as hs-CRP, IL-6, and NT-proBNP can identify patients at high risk for subclinical atherosclerosis, facilitating early intervention.⁸
- **Personalized Therapeutics:** The integration of biomarker data enables tailored treatment strategies, including aggressive lipid-lowering therapies, targeted anti-inflammatory agents (e.g., IL-6 inhibitors), and antiplatelet prophylaxis.⁸
- **Prognostic Assessment:** Biomarkers provide prognostic insights into the likelihood of future CV events, guiding clinical decisions on the intensity of monitoring and treatment.⁸

Emerging biomarkers such as myeloperoxidase (MPO), galectin-3, and circulating microRNAs are under investigation for their potential role in refining CV risk assessment in autoimmune diseases. Advances in multi-omics approaches and artificial intelligence may further enhance the predictive accuracy and clinical applicability of biomarkers in this context.⁹

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

The judicious use of biomarkers holds the promise of transforming the landscape of cardiovascular care in autoimmune diseases. A deeper understanding of their pathophysiological underpinnings and validation in diverse populations will be instrumental in optimizing patient outcomes.⁹

Medical Contraindications for the Use of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases

While biomarkers have significantly advanced the predictive capabilities for cardiovascular (CV) events in patients with autoimmune diseases, their application is not without limitations or contraindications. The following delineates the medical contraindications and challenges in the utilization of biomarkers in this context, emphasizing the importance of careful clinical judgment when incorporating these tools into patient management.⁹

1. Lack of Specificity in Biomarker Elevation

Many biomarkers used in cardiovascular risk prediction, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and interleukin-6 (IL-6), are non-specific markers of inflammation.⁹

- **Contraindication:** Patients with overlapping inflammatory conditions (e.g., infections, malignancies) may exhibit elevated levels of these markers, confounding the interpretation and leading to overestimation of CV risk.¹⁰
- **Clinical Consideration:** Biomarkers must be interpreted in the context of the underlying autoimmune disease and coexisting pathologies.¹⁰

2. Variability in Biomarker Levels

Biomarkers such as troponins and natriuretic peptides can fluctuate due to factors unrelated to autoimmune or cardiovascular pathology.¹⁰

- **Contraindication:** Acute or transient conditions, including dehydration, physical stress, or renal impairment, can alter biomarker levels and diminish their reliability for CV risk assessment.¹⁰
- **Clinical Consideration:** Baseline biomarker levels should be established during disease quiescence to improve interpretive accuracy.¹⁰

3. Comorbid Conditions Affecting Biomarker Accuracy

Comorbidities such as chronic kidney disease (CKD) and liver dysfunction significantly affect the metabolism and clearance of many biomarkers.¹¹

- **Contraindication:** Elevated levels of NT-proBNP or troponins in patients with CKD may not accurately reflect cardiovascular strain, leading to false-positive results.¹¹
- **Clinical Consideration:** Adjustments or alternative markers should be considered in patients with significant organ dysfunction.¹¹

4. Inadequate Standardization of Biomarker Assays

Variability in laboratory methodologies and assay sensitivity can result in inconsistent biomarker measurements across institutions.¹¹

- **Contraindication:** Lack of standardized thresholds for biomarkers like oxidized LDL (oxLDL) or lipoprotein(a) [Lp(a)] may lead to misclassification of cardiovascular risk.¹¹
- **Clinical Consideration:** Clinicians should rely on validated and widely accepted assays to minimize interpretive discrepancies.¹¹

5. Overreliance on Biomarkers in Isolation

The complexity of autoimmune diseases necessitates a comprehensive approach to CV risk assessment.¹²

- **Contraindication:** Sole reliance on biomarkers without integrating clinical, imaging, and functional assessments can result in under- or over-treatment. For instance, a single elevated CRP level may not warrant aggressive CV intervention without corroborating evidence.¹²
- **Clinical Consideration:** Biomarkers should complement, not replace, traditional risk assessment models.¹²

6. Risk of Overtreatment Based on Biomarker Levels

Elevated biomarker levels may lead to unnecessary interventions, including invasive diagnostics or pharmacologic therapies with potential adverse effects.¹²

- **Contraindication:** In patients with mild or clinically stable autoimmune disease, aggressive management based solely on biomarker abnormalities can result in iatrogenic harm, including bleeding complications from antiplatelet therapy or adverse effects from immunosuppressants.¹²
- **Clinical Consideration:** A balanced approach to therapy, guided by the overall clinical picture, is essential to avoid overtreatment.¹²

7. Limited Evidence in Certain Autoimmune Populations

Biomarker data are predominantly derived from studies on common autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Evidence in rarer autoimmune conditions is limited.¹²

- **Contraindication:** Extrapolating biomarker thresholds and predictive value to diseases with distinct pathophysiological mechanisms (e.g., vasculitides or scleroderma) may result in inaccurate risk assessment.¹²
- **Clinical Consideration:** Further research is needed to establish disease-specific biomarker profiles.¹²

8. Genetic and Ethnic Variability

Genetic polymorphisms and ethnic differences can influence biomarker levels and their association with CV risk.¹²

- **Contraindication:** Application of biomarker thresholds validated in one population may not be

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

generalizable to others, potentially leading to misclassification. For instance, elevated Lp(a) levels are more prevalent in certain ethnic groups, complicating risk stratification.¹²

- **Clinical Consideration:** Personalized approaches incorporating genetic and demographic factors are necessary for accurate interpretation.¹³

9. Economic and Resource Constraints

The cost and availability of advanced biomarker assays may limit their applicability in resource-limited settings.¹³

- **Contraindication:** Routine testing of costly biomarkers like myeloperoxidase (MPO) or advanced lipid profiles may not be feasible or cost-effective, particularly in low-resource environments.¹³
- **Clinical Consideration:** The cost-benefit ratio of biomarker testing should be evaluated on a case-by-case basis, prioritizing markers with robust predictive value.^{13,14}

10. Psychological Impact on Patients

Overemphasis on biomarker levels can induce anxiety or undue concern among patients with autoimmune diseases.

- **Contraindication:** Frequent monitoring and reporting of minor biomarker fluctuations may negatively impact patient quality of life without altering clinical outcomes.¹⁴
- **Clinical Consideration:** Clear communication about the role and limitations of biomarkers is crucial to alleviate patient distress.¹⁴

While biomarkers play a pivotal role in predicting cardiovascular events in autoimmune diseases, their use must be guided by an awareness of the contraindications and potential pitfalls. A judicious, multidisciplinary approach that integrates biomarkers with clinical, imaging, and functional data is essential to optimize patient outcomes and minimize the risk of misdiagnosis or overtreatment.¹⁵

The Use of Medical Biomarkers for Predicting Cardiovascular Events in Autoimmune Diseases

The advent of medical biomarkers has been transformative in enhancing the prediction of cardiovascular (CV) events, particularly in patients with autoimmune diseases. These diseases, characterized by chronic systemic inflammation, immune dysregulation, and autoantibody production, predispose individuals to accelerated atherosclerosis, endothelial dysfunction, and increased cardiovascular morbidity and mortality. Biomarkers serve as measurable indicators of biological processes, disease activity, or treatment responses, offering invaluable insights into subclinical cardiovascular risk and guiding therapeutic interventions.¹⁵

1. Role of Biomarkers in Understanding Pathophysiology

Autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and systemic sclerosis contribute to unique pathophysiological pathways driving

cardiovascular risk. Biomarkers help unravel these mechanisms by detecting:

- **Inflammatory activity:** Chronic inflammation accelerates endothelial injury and vascular dysfunction, hallmarks of autoimmune-associated atherosclerosis. Biomarkers such as C-reactive protein (CRP) and interleukin-6 (IL-6) directly quantify systemic inflammation.¹⁵
- **Endothelial dysfunction:** Biomarkers like asymmetric dimethylarginine (ADMA) and vascular adhesion molecules (e.g., VCAM-1) provide insights into vascular health and endothelial integrity.¹⁵
- **Thrombogenic risk:** Autoimmune diseases often involve hypercoagulability mediated by antiphospholipid antibodies (aPLs) or dysregulated platelet activation. Biomarkers in coagulation pathways help stratify thrombotic risk.¹⁵

2. Biomarkers for Risk Stratification and Early Detection

The use of biomarkers allows clinicians to stratify patients into different risk categories, enabling tailored monitoring and treatment. Key biomarkers include:

- **High-Sensitivity C-Reactive Protein (hs-CRP):** Elevated hs-CRP levels are predictive of atherosclerotic plaque formation and instability, particularly in autoimmune populations where inflammation is chronic.¹⁶
 - **Clinical Application:** hs-CRP is routinely used to identify patients with subclinical cardiovascular disease and guide decisions regarding anti-inflammatory therapies or lipid-lowering agents.¹⁶
- **Interleukin-6 (IL-6):** IL-6 acts as a pivotal cytokine in autoimmune disease activity, promoting systemic inflammation and vascular dysfunction.¹⁶
 - **Clinical Application:** IL-6 levels can predict adverse CV outcomes and may indicate candidates for IL-6-targeted therapies (e.g., tocilizumab).¹⁶
- **Troponins (hs-TnI, hs-TnT):** High-sensitivity troponins, even at low levels, are markers of myocardial injury and correlate with cardiovascular events in RA and SLE.¹⁶
 - **Clinical Application:** Their utility extends to identifying patients at risk for subclinical myocarditis or silent ischemia in autoimmune contexts.¹⁶
- **Lipoprotein(a) [Lp(a)]:** Elevated Lp(a) is common in autoimmune diseases and exacerbates atherosclerotic and thrombotic processes.¹⁷

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

- **Clinical Application:** Measurement of Lp(a) can help identify patients requiring aggressive lipid management strategies.¹⁷
- **Anti-Phospholipid Antibodies (aPL):** These antibodies, including lupus anticoagulant, anticardiolipin, and anti- β 2 glycoprotein I, are strongly associated with arterial and venous thrombotic events.¹⁷
 - **Clinical Application:** Detection of aPLs is essential in diagnosing antiphospholipid syndrome (APS) and assessing stroke and myocardial infarction risk.¹⁷

3. Integration of Biomarkers with Imaging and Functional Assessments

Biomarkers are increasingly used in conjunction with imaging techniques to improve cardiovascular risk prediction in autoimmune diseases.

- **Carotid Intima-Media Thickness (CMT):** Elevated hs-CRP or IL-6 levels correlate with increased CMT, a surrogate marker of subclinical atherosclerosis.¹⁷
- **Coronary Artery Calcium Score (CACS):** Biomarker profiles, including Lp(a) and ADMA, can enhance the predictive accuracy of CACS for coronary artery disease (CAD).¹⁷

4. Biomarkers as Therapeutic Targets

Many biomarkers not only serve as indicators of risk but also represent potential therapeutic targets.

- **IL-6 Inhibition:** Therapies targeting IL-6 (e.g., tocilizumab) demonstrate reductions in both autoimmune disease activity and CV events, particularly in RA.¹⁷
- **PCSK9 Inhibitors:** Elevated Lp(a) levels are effectively managed with PCSK9 inhibitors, reducing atherosclerotic burden in high-risk populations.¹⁷
- **Antiplatelet Therapy in APS:** The presence of aPLs informs the need for antiplatelet or anticoagulation strategies to mitigate thrombotic risk.¹⁷

5. Longitudinal Monitoring of Disease Activity and Cardiovascular Risk

Biomarkers allow for dynamic monitoring of cardiovascular and autoimmune disease progression:

- **NT-proBNP:** Elevated levels reflect cardiac stress and can predict heart failure development, particularly in SLE patients with lupus myocarditis.¹⁷
- **Myeloperoxidase (MPO):** MPO levels, indicative of oxidative stress, correlate with plaque instability and may predict acute coronary syndrome.¹⁷

6. Personalized Medicine Through Biomarkers

The integration of biomarker data into clinical practice fosters a personalized approach to care.

- **Risk Prediction Models:** Tools such as the Reynolds Risk Score incorporate hs-CRP to refine cardiovascular risk prediction in autoimmune populations.¹⁸
- **Pharmacogenomics:** Genetic polymorphisms influencing biomarker expression (e.g., IL-6 receptor variants) guide personalized therapy selection.¹⁸

7. Future Directions and Emerging Biomarkers

Advances in omics technologies have led to the discovery of novel biomarkers with potential applications in autoimmune disease-related cardiovascular risk prediction:

- **Circulating MicroRNAs:** These small RNA molecules regulate immune and cardiovascular pathways and show promise as highly sensitive biomarkers.¹⁸
- **Galectin-3:** This marker of fibrosis and inflammation may provide insights into cardiac remodeling in autoimmune populations.¹⁸
- **Multi-Biomarker Panels:** Combining inflammatory, endothelial, and cardiac biomarkers into composite risk scores enhances predictive accuracy.¹⁸

The use of biomarkers represents a paradigm shift in predicting cardiovascular events in autoimmune diseases. Their integration into routine clinical practice facilitates early detection, precise risk stratification, and personalized treatment strategies, ultimately improving outcomes for this high-risk population. Continued research into novel biomarkers and their mechanistic roles will further refine their utility and expand their applications in autoimmune cardiovascular care.¹⁸

CONCLUSION

The role of biomarkers in predicting cardiovascular events in autoimmune diseases represents a transformative advancement in precision medicine. Autoimmune disorders, characterized by systemic inflammation, immune dysregulation, and endothelial dysfunction, are intrinsically linked to a heightened risk of cardiovascular morbidity and mortality. Within this context, biomarkers emerge as indispensable tools, enabling clinicians to identify at-risk individuals, unravel underlying pathophysiological mechanisms, and guide targeted therapeutic interventions. Biomarkers such as high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and antiphospholipid antibodies (aPLs) offer robust insights into inflammatory and thrombotic pathways, bridging the gap between disease activity and cardiovascular risk. Novel biomarkers like circulating microRNAs and galectin-3 have further expanded our understanding of the complex interplay between autoimmune pathophysiology and cardiovascular health, opening avenues for innovative diagnostic and therapeutic strategies.

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

Importantly, the integration of biomarkers into cardiovascular risk assessment allows for a more nuanced stratification of patients, especially when combined with imaging modalities like carotid intima-media thickness (CIMT) or coronary artery calcium scoring (CACS). Such a multi-faceted approach not only enhances early detection of subclinical atherosclerosis but also informs decisions regarding preventive therapies, ranging from aggressive lipid management with PCSK9 inhibitors to targeted anti-inflammatory treatments like IL-6 receptor antagonists.

Beyond risk stratification, biomarkers facilitate longitudinal monitoring of both autoimmune disease activity and cardiovascular risk. Biomarkers such as NT-proBNP and troponins offer real-time insights into myocardial strain and injury, enabling timely intervention in patients at risk for heart failure or silent myocardial ischemia. Moreover, advancements in multi-biomarker panels and risk prediction models further optimize clinical decision-making by providing comprehensive assessments of individualized risk profiles.

However, the widespread implementation of biomarkers in clinical practice is not without challenges. Variability in biomarker expression across different autoimmune diseases, the potential for confounding factors, and the need for standardized cut-off values underscore the importance of context-specific interpretation and clinical correlation. Furthermore, the high cost of certain assays and the limited availability of advanced testing in resource-constrained settings pose additional barriers to equitable access and utilization.

Looking ahead, the evolving landscape of biomarker research promises to further revolutionize cardiovascular care in autoimmune populations. As omics technologies advance and our understanding of molecular pathways deepens, the discovery of novel biomarkers and their incorporation into personalized medicine approaches will likely redefine the standard of care. Future studies should focus on validating emerging biomarkers, refining risk prediction models, and exploring their role as therapeutic targets in clinical trials.

Biomarkers are pivotal in addressing the unique cardiovascular challenges faced by patients with autoimmune diseases. By bridging the gap between pathophysiology and clinical application, they empower clinicians to anticipate, prevent, and manage cardiovascular events with unparalleled precision. Ultimately, the judicious use of biomarkers has the potential to improve outcomes, reduce healthcare disparities, and enhance the quality of life for this vulnerable population. Continued research and interdisciplinary collaboration will be essential to fully realize the transformative potential of biomarkers in autoimmune-related cardiovascular care.

REFERENCES

I. The global burden of cardiovascular diseases and risk: a compass for future health. Vaduganathan M,

Mensah GA, Turco JV, Fuster V, Roth GA. *J Am Coll Cardiol.* 2022;80:2361–2371. doi: 10.1016/j.jacc.2022.11.005.

- II. Emerging biomarkers for the detection of cardiovascular diseases. Thupakula S, Nimmala SS, Ravula H, Chekuri S, Padiya R. *Egypt Heart J.* 2022;74:77. doi: 10.1186/s43044-022-00317-2.
- III. Global trends and regional differences in incidence and mortality of cardiovascular disease, 1990-2019: findings from 2019 global burden of disease study. Li Y, Cao GY, Jing WZ, Liu J, Liu M. *Eur J Prev Cardiol.* 2023;30:276–286. doi: 10.1093/eurjpc/zwac285
- IV. Epidemiology of coronary heart disease and acute coronary syndrome. Sanchis-Gomar F, Perez-Quilis C, Leischik R, Lucia A. *Ann Transl Med.* 2016;4:256. doi: 10.21037/atm.2016.06.33.
- V. Circulating biomarkers for cardiovascular disease risk prediction in patients with cardiovascular disease. Wong YK, Tse HF. *Front Cardiovasc Med.* 2021;8:713191. doi: 10.3389/fcvm.2021.713191.
- VI. The Framingham Risk Score: an appraisal of its benefits and limitations. Hemann BA, Bimson WF, Taylor AJ. *Am Heart Hosp J.* 2007;5:91–96. doi: 10.1111/j.1541-9215.2007.06350.x.
- VII. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Chow SL, Maisel AS, Anand I, et al. *Circulation.* 2017;135:0–91. doi: 10.1161/CIR.0000000000000490.
- VIII. Biomarkers in cardiovascular disease: Statistical assessment and section on key novel heart failure biomarkers. Dhingra R, Vasan RS. *Trends Cardiovasc Med.* 2017;27:123–133. doi: 10.1016/j.tcm.2016.07.005.
- IX. Dasgupta A, Wahed A. Elsevier. 2. Science Direct: Elsevier; 2021. Cardiac markers. *Clinical Chemistry, Immunology and Laboratory Quality Control* ; pp. 149–171
- X. Novel biomarkers for cardiovascular risk prediction. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409355/pdf/jgc-14-02-135.pdf>. *J Geriatr Cardiol.* 2017;14:135–150. doi:10.11909/j.issn.1671-5411.2017.02.008.
- XI. Hospital laboratory reporting may be a barrier to detection of 'microsize' myocardial infarction in the US: an observational study. Safford MM, Parmar G, Barasch CS, et al. *BMC Health Serv Res.* 2013;13:162. doi: 10.1186/1472-6963-13-162.
- XII. Third universal definition of myocardial infarction. Thygesen K, Alpert JS, Jaffe AS, et al. *Eur Heart J.* 2012;33:2551–2567.

The Role of Biomarkers in Predicting Cardiovascular Events in Autoimmune Diseases: Insights into Early Detection and Risk Stratification

- XIII. Preparing the United States for high-sensitivity cardiac troponin assays. Korley FK, Jaffe AS. *J Am Coll Cardiol*. 2013;61:1753–1758. doi: 10.1016/j.jacc.2012.09.069.
- XIV. Fatty acid-binding proteins as plasma markers of tissue injury. Pellers MM, Hermens WT, Glatz JF. *Clin Chim Acta*. 2005;352:15–35. doi: 10.1016/j.cccn.2004.09.001.
- XV. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Devaraj S, Xu DY, Jialal I. *Circulation*. 2003;107:398–404. doi: 10.1161/01.cir.0000052617.91920.fd.
- XVI. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: Endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. *Atherosclerosis*. 2015;241:507–532. doi: 10.1016/j.atherosclerosis.2015.05.007.
- XVII. Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Wiklund FE, Bennet AM, Magnusson PK, et al. *Aging Cell*. 2010;9:1057–1064. doi: 10.1111/j.1474-9726.2010.00629.x.
- XVIII. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Danesh J, Lewington S, Thompson SG, et al. *JAMA*. 2005;294:1799–1809. doi: 10.1001/jama.294.14.1799.